`
`OPENINGS™ Patient Support Program from Alcon
`
`http://www.myglaucomasupport.com/openingspatientsupportprogram.shtml?
`
`Go
`
`48 captures
`21 Aug 13 8 Nov 16
`
`OPENINGS Patient Support Program
`
`™
`
`FEB MAR APR
`
`29
`
`Close
`
`2013 2014 2015
`
`Help
`
`ENROLL
`Need a Program Savings Card?* Enroll in the
`OPENINGS Patient Support Program to
`™
`download one now, plus get access to other
`valuable program benefits.
`Enroll Now ›
`
`ACTIVATE
`Already have a Program Savings Card?
`Activate Now ›
`
`Already Registered?
`Log In Now › to update your reminders, access
`materials and more.
`
`Benefits of the Program
`Your doctor wants to help you and so do we. The OPENINGS Patient Support Program has
`™
`been designed to also give you valuable information and helpful reminder tools. Enroll now in
`the OPENINGS Patient Support Program, powered by the EyeFile System, to receive
`™
`™
`materials by email and mail that will help you to better understand your condition, what you
`can do about it, and what may lie ahead in your treatment plan, plus additional eye care
`related resources. Enrolling takes just a minute or two, and is free.
`
`Click here for full Program Savings Card Terms and Conditions ›
`Eligible patients may pay no more than $25 for
`*
`their Alcon prescriptions
`Start saving on each 30day supply of the Alcon IOPlowering eyedrops you’ve been
`prescribed, now through 12/31/14 with a Program Savings Card from the OPENINGS
`™
`Patient Support Program.
`
`Your Program Savings Card can help make it a little easier to stay on track with your
`TRAVATAN Z Solution (travoprost ophthalmic solution) 0.004%, SIMBRINZA Suspension
`®
`®
`(brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%, or AZOPT Suspension
`®
`(brinzolamide ophthalmic suspension) 1% by helping to make your refills more affordable.
`Here's how:
`
`If you fill your prescription each month, you pay as little as $25 and Alcon will pay the
`remaining cost, up to $105 for each 30day supply.
`If you fill your prescription every 3 months, you pay as little as $50 and Alcon will pay the
`remaining cost, up to $365 for each 90day supply.
`How to Use Your Program Savings Card
`Using your Program Savings Card from the OPENINGS Patient Support Program is easy. If
`™
`eligible, simply take your activated Program Savings Card to the pharmacy (click here if you
`need to activate your card) along with your prescription. The Program Savings Card is good
`for multiple uses and can be used for prescriptions of TRAVATAN Z Solution, SIMBRINZA
`®
`®
`Suspension and AZOPT Suspension. Be sure to present your Program Savings Card at the
`®
`pharmacy each time you fill your prescription for any of these products.
`
`If you order your Alcon prescriptions by mail and you are eligible for savings, you can still
`take advantage of the savings on your prescriptions filled by mail order even if they do not
`accept Program Savings Cards. Simply follow these easy steps:
`
`1. Start by asking your mail order facility if they accept the Program Savings Card.
`
`2. If not, collect the following information:
`
`The 11digit ID# and GRP# that are found in the upper left hand corner of your
`Program Savings Card; If you prefer, you can make a photocopy of the front of the
`Program Savings Card instead
`Your original receipt (which should include the mailorder pharmacy name, product
`name, prescription number or Rx#, date filled, quantity, and price you paid)
`A 3x5 index card with your name, address, city, state, zip code, phone number, and the
`amount of money you paid for your prescription (your “out of pocket” expense)
`
`Exhibit 1033
`ARGENTUM
`http://web.archive.org/web/20140329091929/http://www.myglaucomasupport.com/openingspatientsupportprogram.shtml?
`
`Mail all of this information to:
`OPENINGS Patient Support Program
`™
`Claims Processing Dept
`
`1/4
`
`000001
`
`
`
`2/24/2017
`
`48 captures
`21 Aug 13 8 Nov 16
`
`OPENINGS™ Patient Support Program from Alcon
`PO Box 7017
`http://www.myglaucomasupport.com/openingspatientsupportprogram.shtml?
`Bedminster, NJ 079217017
`
`Go
`
`For questions regarding this process, please call 8668752455.
`
`ACTIVATE YOUR PROGRAM SAVINGS CARD
`
`ENROLL NOW
`
`FEB MAR APR
`
`29
`
`Close
`
`2013 2014 2015
`
`Help
`
`Already Registered? Log In Now › to update your reminders, access materials and more.
`Click here for full Program Savings Card Terms and Conditions ›
`
`This offer is not valid for patients who are enrolled in Medicare Part D, Medicaid, Medigap, VA, DOD, Tricare, or any
`*
`other governmentrun or governmentsponsored health care program with a pharmacy benefit. If you are not eligible for
`the Program Savings Card, you can still enjoy all the other benefits of the OPENINGS Patient Support Program.
`™
`
`Important information about
`TRAVATAN Z (travoprost ophthalmic
`®
`solution) 0.004%
`
`Important information about
`SIMBRINZA (brinzolamide/brimonidine
`®
`tartrate ophthalmic suspension) 1%/0.2%
`
`Important information about
`AZOPT (brinzolamide ophthalmic
`®
`suspension) 1%
`
`® ®
`
`INDICATIONS AND USAGE
`TRAVATAN Z Solution is indicated for the
`®
`reduction of elevated intraocular pressure (IOP)
`in patients with openangle glaucoma or ocular
`hypertension.
`Dosing and Administration
`The recommended dosage is one drop in the
`affected eye(s) once daily in the evening.
`TRAVATAN Z Solution should not be
`®
`administered more than once daily since it has
`been shown that more frequent administration
`of prostaglandin analogs may decrease the
`IOP lowering effect.
`TRAVATAN Z Solution may be used
`®
`concomitantly with other topical ophthalmic
`drug products to lower IOP. If more than one
`topical ophthalmic drug is being used, the
`drugs should be administered at least five (5)
`minutes apart.
`IMPORTANT SAFETY INFORMATION
`Warnings and Precautions
`Pigmentation Travoprost ophthalmic solution
`has been reported to increase the pigmentation
`of the iris, periorbital tissue (eyelid) and
`eyelashes. Pigmentation is expected to
`increase as long as travoprost is administered.
`After discontinuation of travoprost,
`pigmentation of the iris is likely to be
`permanent, while pigmentation of the periorbital
`tissue and eyelash changes have been
`reported to be reversible in some patients. The
`long term effects of increased pigmentation are
`not known. While treatment with TRAVATAN Z
`®
`Solution can be continued in patients who
`develop noticeably increased iris pigmentation,
`these patients should be examined regularly.
`Eyelash Changes TRAVATAN Z Solution
`®
`may gradually change eyelashes and vellus
`hair in the treated eye. These changes include
`increased length, thickness, and number of
`lashes. Eyelash changes are usually reversible
`upon discontinuation of treatment.
`Intraocular Inflammation TRAVATAN Z
`®
`Solution should be used with caution in patients
`
`INDICATIONS AND USAGE
`SIMBRINZA Suspension is a fixed
`®
`combination indicated in the reduction of
`elevated intraocular pressure (IOP) in patients
`with openangle glaucoma or ocular
`hypertension.
`Dosage and Administration
`The recommended dose is one drop of
`SIMBRINZA Suspension in the affected
`eye(s) three times daily. Shake well before use.
`SIMBRINZA Suspension may be used
`concomitantly with other topical ophthalmic
`drug products to lower intraocular pressure. If
`more than one topical ophthalmic drug is being
`used, the drugs should be administered at least
`five (5) minutes apart.
`IMPORTANT SAFETY INFORMATION
`Contraindications
`SIMBRINZA Suspension is contraindicated in
`®
`patients who are hypersensitive to any
`component of this product and neonates and
`infants under the age of 2 years.
`Warnings and Precautions
`Sulfonamide Hypersensitivity Reactions
`Brinzolamide is a sulfonamide, and although
`administered topically, is absorbed
`systemically. Sulfonamide attributable adverse
`reactions may occur. Fatalities have occurred
`due to severe reactions to sulfonamides.
`Sensitization may recur when a sulfonamide is
`readministered irrespective of the route of
`administration. If signs of serious reactions or
`hypersensitivity occur, discontinue the use of
`this preparation.
`Corneal Endothelium—There is an increased
`potential for developing corneal edema in
`patients with low endothelial cell counts.
`Severe Hepatic or Renal Impairment (CrCl <30
`mL/min)—SIMBRINZA Suspension has not
`®
`been specifically studied in these patients and
`is not recommended.
`Acute AngleClosure Glaucoma—The
`management of patients with acute angle
`closure glaucoma requires therapeutic
`http://web.archive.org/web/20140329091929/http://www.myglaucomasupport.com/openingspatientsupportprogram.shtml?
`
`INDICATIONS AND USAGE
`AZOPT Suspension is a carbonic anhydrase
`®
`inhibitor (CAI) indicated in the treatment of
`elevated intraocular pressure in patients with
`ocular hypertension or openangle glaucoma.
`Dosage and Administration
`The recommended dose is one drop of
`AZOPT Suspension in the affected eye(s)
`®
`three times daily. If more than one topical
`ophthalmic drug is being used, the drugs
`should be administered at least ten (10)
`minutes apart.
`IMPORTANT SAFETY INFORMATION
`Contraindications
`AZOPT Suspension is contraindicated in
`®
`patients who are hypersensitive to any
`component of this product.
`Warnings and Precautions
`Sulfonamide Hypersensitivity Reactions
`AZOPT Suspension is a sulfonamide and
`®
`although administered topically it is absorbed
`systemically. The same types of adverse
`reactions that are attributable to sulfonamides
`may occur with topical administration of
`AZOPT Suspension. Fatalities have occurred,
`®
`although rarely, due to severe reactions to
`sulfonamides. Sensitization may recur when a
`sulfonamide is readministered irrespective of
`the route of administration. If signs of serious
`reactions or hypersensitivity occur, discontinue
`the use.
`Corneal Endothelium Carbonic anhydrase
`activity has been observed in both the
`cytoplasm and around the plasma membranes
`of the corneal endothelium. There is an
`increased potential for developing corneal
`edema in patients with low endothelial cell
`counts. Caution should be used when
`prescribing AZOPT Suspension to this group
`®
`of patients.
`Severe Renal Impairment AZOPT
`®
`Suspension has not been studied in patients
`with severe renal impairment (CrCl ≥ 30
`mL/min). Because AZOPT Suspension and its
`®
`
`2/4
`
`000002
`
`
`
`OPENINGS™ Patient Support Program from Alcon
`2/24/2017
`metabolite are excreted predominantly by the
`interventions in addition to ocular hypotensive
`with active intraocular inflammation (e.g.,
`FEB MAR APR
`Close
`http://www.myglaucomasupport.com/openingspatientsupportprogram.shtml?
`Go
`29
`kidney, AZOPT Suspension is not
`agents. SIMBRINZA Suspension has not
`uveitis) because the inflammation may be
`®
`®
`48 captures
`exacerbated.
`recommended in such patients.
`been studied in patients with acute angle
`2013 2014 2015
`21 Aug 13 8 Nov 16
`closure glaucoma.
`Macular Edema Macular edema, including
`Acute AngleClosure Glaucoma The
`cystoid macular edema, has been reported
`management of patients with acute angle
`Contact Lens Wear—The preservative in
`during treatment with travoprost ophthalmic
`closure glaucoma requires therapeutic
`SIMBRINZA Suspension, benzalkonium
`®
`solution. TRAVATAN Z Solution should be
`interventions in addition to ocular hypotensive
`chloride, may be absorbed by soft contact
`®
`agents. AZOPT Suspension has not been
`used with caution in aphakic patients, in
`lenses. Contact lenses should be removed
`®
`pseudophakic patients with a torn posterior
`studied in patients with acute angleclosure
`during instillation of SIMBRINZA Suspension
`®
`lens capsule, or in patients with known risk
`glaucoma.
`but may be reinserted 15 minutes after
`factors for macular edema.
`instillation.
`Contact Lens Wear The preservative in
`Angleclosure, Inflammatory or Neovascular
`AZOPT Suspension, benzalkonium chloride,
`Severe Cardiovascular Disease—Brimonidine
`®
`Glaucoma TRAVATAN Z Solution has not
`may be absorbed by soft contact lenses.
`tartrate, a component of SIMBRINZA
`®
`®
`been evaluated for the treatment of angle
`Contact lenses should be removed during
`Suspension, had a less than 5% mean
`closure, inflammatory or neovascular
`instillation, but may be reinserted 15 minutes
`decrease in blood pressure 2 hours after
`glaucoma.
`after instillation.
`dosing in clinical studies; caution should be
`exercised in treating patients with severe
`Bacterial Keratitis There have been reports of
`Adverse Reactions
`cardiovascular disease.
`bacterial keratitis associated with the use of
`In clinical studies of AZOPT Suspension, the
`®
`multipledose containers of topical ophthalmic
`Potentiation of Vascular Insufficiency—
`most frequently reported adverse events
`products. These containers had been
`Brimonidine tartrate, a component of
`reported in 510% of patients were blurred
`inadvertently contaminated by patients who, in
`SIMBRINZA Suspension, may potentiate
`®
`vision and bitter, sour or unusual taste. Adverse
`most cases, had a concurrent corneal disease
`syndromes associated with vascular
`events occurring in 15% of patients were
`or a disruption of the ocular epithelial.
`insufficiency. It should be used with caution in
`blepharitis,dermatitis, dry eye, foreign body
`patients with depression, cerebral or coronary
`Use with Contact Lenses Contact lenses
`sensation, headache, hyperemia, ocular
`insufficiency, Raynaud’s phenomenon,
`should be removed prior to instillation of
`discharge, ocular discomfort, ocular keratitis,
`orthostatic hypotension, or Thromboangiitis
`TRAVATAN Z Solution and may be reinserted
`ocular pain, ocular pruritus and rhinitis.
`®
`obliterans.
`15 minutes following its administration.
`Drug Interactions
`Contamination of Topical Ophthalmic Products
`Adverse Reactions
`Oral Carbonic Anhydrase Inhibitors There is a
`After Use—There have been reports of
`The most common adverse reaction observed
`potential for an additive effect on the known
`bacterial keratitis associated with the use of
`in controlled clinical studies with TRAVATAN Z
`systemic effects of carbonic anhydrase
`®
`multipledose containers of topical ophthalmic
`inhibition in patients receiving an oral CAI and
`Solution was ocular hyperemia which was
`products. These containers have been
`AZOPT Suspension. The concomitant
`reported in 30 to 50% of patients. Up to 3% of
`®
`inadvertently contaminated by patients who, in
`patients discontinued therapy due to
`administration of AZOPT Suspension and oral
`most cases, had a concurrent corneal disease
`®
`conjunctival hyperemia. Ocular adverse
`CAIs is not recommended.
`or a disruption of the ocular epithelial surface.
`reactions reported at an incidence of 5 to 10%
`HighDose Salicylate Therapy In patients
`Adverse Reactions
`in these clinical studies included decreased
`treated with oral CAIs, rare instances of
`visual acuity, eye discomfort, foreign body
`SIMBRINZA Suspension
`acidbase alterations have occurred with high
`sensation, pain and pruritus. In postmarketing
`In two clinical trials of 3 months’ duration with
`dose salicylate therapy. Therefore, the potential
`use with prostaglandin analogs, periorbital and
`SIMBRINZA Suspension, the most frequent
`for such drug interactions should be considered
`lid changes including deepening of the eyelid
`in patients receiving AZOPT Suspension.
`reactions associated with its use occurring in
`®
`sulcus have been observed.
`approximately 35% of patients in descending
`Click here for full prescribing information
`order of incidence included: blurred vision, eye
`Use in Specific Populations
`for AZOPT Suspension
`®
`irritation, dysgeusia (bad taste), dry mouth, and
`Use in pediatric patients below the age of 16
`You are encouraged to report negative side
`eye allergy. Adverse reaction rates with
`years is not recommended because of potential
`effects of prescription drugs to the FDA. Visit
`SIMBRINZA Suspension were comparable to
`®
`safety concerns related to increased
`www.fda.gov/medwatch, or call 1800FDA
`those of the individual components. Treatment
`pigmentation following longterm chronic use.
`1088.
`discontinuation, mainly due to adverse
`Click here for full prescribing information
`reactions, was reported in 11% of SIMBRINZA
`®
`for TRAVATAN Z Solution
`®
`Suspension patients.
`You are encouraged to report negative side
`Brinzolamide 1%
`effects of prescription drugs to the FDA. Visit
`In clinical studies of brinzolamide ophthalmic
`www.fda.gov/medwatch, or call 1800FDA
`suspension 1%, the most frequently reported
`1088.
`adverse events reported in 510% of patients
`were blurred vision and bitter, sour, or unusual
`taste. Adverse events occurring in 15% of
`patients were blepharitis, dermatitis, dry eye,
`foreign body sensation, headache, hyperemia,
`ocular discharge, ocular discomfort, ocular
`keratitis, ocular pain, ocular pruritus, and
`rhinitis.
`Brimonidine Tartrate 0.2%
`In clinical studies of brimonidine tartrate 0.2%,
`adverse events occurring in approximately 10
`30% of the subjects, in descending order of
`
`® ®
`
`Help
`
`http://web.archive.org/web/20140329091929/http://www.myglaucomasupport.com/openingspatientsupportprogram.shtml?
`
`3/4
`
`000003
`
`
`
`FEB MAR APR
`
`29
`
`Close
`
`2013 2014 2015
`
`Help
`
`2/24/2017
`
`48 captures
`21 Aug 13 8 Nov 16
`
`Go
`
`OPENINGS™ Patient Support Program from Alcon
`incidence, included oral dryness, ocular
`http://www.myglaucomasupport.com/openingspatientsupportprogram.shtml?
`hyperemia, burning and stinging, headache,
`blurring, foreign body sensation,
`fatigue/drowsiness, conjunctival follicles, ocular
`allergic reactions, and ocular pruritus.
`Events occurring in approximately 39% of the
`subjects, in descending order, included corneal
`staining/erosion, photophobia, eyelid erythema,
`ocular ache/pain, ocular dryness, tearing,
`upper respiratory symptoms, eyelid edema,
`conjunctival edema, dizziness, blepharitis,
`ocular irritation, gastrointestinal symptoms,
`asthenia, conjunctival blanching, abnormal
`vision, and muscular pain.
`Drug Interactions—Consider the following
`when prescribing SIMBRINZA Suspension:
`®
`Concomitant administration with oral carbonic
`anhydrase inhibitors is not recommended due
`to the potential additive effect. Use with high
`dose salicylate may result in acidbase and
`electrolyte alterations. Use with CNS
`depressants may result in an additive or
`potentiating effect. Use with
`antihypertensives/cardiac glycosides may
`result in additive or potentiating effect on
`lowering blood pressure. Use with tricyclic
`antidepressants may blunt the hypotensive
`effect of systemic clonidine and it is unknown if
`use with this class of drugs interferes with IOP
`lowering. Use with monoamine oxidase
`inhibitors may result in increased hypotension.
`Click here for full prescribing information
`for SIMBRINZA Suspension
`®
`You are encouraged to report negative side
`effects of prescription drugs to the FDA. Visit
`www.fda.gov/medwatch, or call 1800FDA
`1088.
`
`http://web.archive.org/web/20140329091929/http://www.myglaucomasupport.com/openingspatientsupportprogram.shtml?
`
`4/4
`
`000004
`
`